Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Anlotinib Maintenance in ES-SCLC
NCT04620837Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and anlotinib in small cell lung cancer (SCLC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Rate of progression free survival at 6 months. Status: unknown.
02
Drugs
tislelizumabanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04620837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620837.